The aryl hydrocarbon receptor (AHR) as a potential target for the control of intestinal inflammation: insights from an immune and bacteria sensor receptor L Pernomian, M Duarte-Silva, CR de Barros Cardoso Clinical reviews in allergy & immunology 59 (3), 382-390, 2020 | 161 | 2020 |
Reappraisal of antibodies against Saccharomyces cerevisiae (ASCA) as persistent biomarkers in quiescent Crohn’s disease M Duarte-Silva, PC Afonso, PR de Souza, BC Peghini, ... Autoimmunity 52 (1), 37-47, 2019 | 25 | 2019 |
Peroxisome proliferator-activated receptor alpha mediates the beneficial effects of atorvastatin in experimental colitis PJ Basso, H Sales-Campos, V Nardini, M Duarte-Silva, VBF Alves, ... Frontiers in Immunology 12, 618365, 2021 | 15 | 2021 |
Reciprocally Divergent Levels of Testosterone and Dihydrotestosterone Accompany Patterns of Androgen Receptor Pathway Signaling to Dictate COVID-19 Outcomes in Men M Duarte-Silva, CNS Oliveira, CA Fuzo, PVSN Silva-Neto, DM Toro, ... | 3 | 2022 |
Divergent androgenic modulation of SARS-CoV-2 infection cooperates with dysregulated immune response to dictate worse COVID-19 outcomes in men M Duarte-Silva, CNS Oliveira, C Fuzo, PV Silva-Neto, DM Toro, ... Brain, behavior, and immunity 114, 275-286, 2023 | 2 | 2023 |
Cinnamaldehyde modulates host immunoinflammatory responses in rat ligature-induced periodontitis and peripheral blood mononuclear cell models ICV de Oliveira, LV Galvão-Moreira, JL Vilela, M Duarte-Silva, ... International Immunopharmacology 115, 109669, 2023 | 2 | 2023 |
Traditional drugs: mechanisms of immunosuppressor and corticosteroid therapies for inflammatory bowel diseases CR de Barros Cardoso, A de Castro Habka, CF Pinzan, CNS Oliveira, ... Biological Therapy for Inflammatory Bowel Disease, 2019 | 2 | 2019 |
Leukocyte dysfunction and reduced CTLA-4 expression are associated with perianal Crohn’s disease M Duarte-Silva, RS Parra, MR Feitosa, V Nardini, SR Maruyama, ... Clinical and Experimental Immunology 217 (1), 78-88, 2024 | | 2024 |
P038 Persistent inflammatory markers and deregulated immune response in clinical remission Crohn's disease patients treated with infliximab DS Murillo, P Rogerio, F Marley, F Omar, RJ Joaquim, C Cristina Official journal of the American College of Gastroenterology| ACG 114, S10-S11, 2019 | | 2019 |
P085 Crohn’s disease patients under combined therapy with Azathioprine and Infliximab present persistent inflammation together with a counter regulatory response during … M Duarte-Silva, RS Parra, MR Feitosa, O Féres, JJ Ribeiro da Rocha, ... Journal of Crohn's and Colitis 13 (Supplement_1), S127-S128, 2019 | | 2019 |